Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
Disclaimer & DisclosureReport an Issue
